CJC-1295

CJC-1295 began as a modification of Sermorelin (the first 29 amino acids of GHRH) with several amino acid substitutions to resist enzymatic degradation. The DAC (Drug Affinity Complex) modification — the addition of a lysine chain that binds to albumin in the bloodstream — extends the half-life from approximately 30 minutes (the Mod GRF 1-29 version without DAC) to 6–8 days, allowing once or twice weekly dosing. This extended half-life comes with an important trade-off: rather than producing discrete, physiologically pulsatile GH pulses, CJC-1295 with DAC creates sustained, continuous GH release — what is often called "GH bleed." Natural GH pulsatility is considered by many practitioners to be important for maintaining receptor sensitivity and avoiding the metabolic side effects of chronically elevated GH. This concern drives some practitioners toward Mod GRF 1-29 (CJC-1295 without DAC) despite its more frequent injection requirement. Most CJC-1295 protocols are combined with Ipamorelin, which acts through the complementary ghrelin receptor pathway. The combination of GHRH-pathway stimulation (CJC-1295) and ghrelin-pathway stimulation (Ipamorelin) produces synergistically amplified GH pulses.

IGF-1 elevation is the primary documented benefit. Clinical studies with CJC-1295 demonstrated significant, dose-dependent IGF-1 increases that were sustained for weeks after a single injection at higher doses — a unique pharmacokinetic profile among GHRH analogs. Elevated IGF-1 drives improvements in lean mass, fat metabolism, connective tissue health, and recovery. Convenience from once or twice weekly dosing is a meaningful practical benefit. Daily injection regimens are a significant adherence barrier; CJC-1295's weekly dosing substantially reduces this friction while maintaining meaningful GH axis elevation. Synergy with Ipamorelin is the most exploited characteristic. The CJC-1295 + Ipamorelin combination is arguably the most popular GH optimization stack in the research community precisely because the two peptides act through different receptors (GHRH-R and GHS-R respectively), producing additive GH release that exceeds either alone.

Water retention is common and proportional to GH/IGF-1 elevation. The sustained GH release from CJC-1295 DAC can cause persistent mild edema, particularly in the extremities, that is more difficult to manage than the episodic retention from pulsatile protocols. Flushing and localized redness at the injection site occur in some users, consistent with other GHRH analogs. The "GH bleed" concern: Some practitioners argue that continuous, non-pulsatile GH release from CJC-1295 DAC may blunt pituitary GHRH receptor sensitivity over time and produce the metabolic side effects (insulin resistance, joint discomfort) associated with chronically elevated GH. This is the primary reason some users prefer Mod GRF 1-29 (without DAC) despite more frequent injections. IGF-1 levels at higher doses may become supraphysiological, which carries the same theoretical cancer concern as other GH-elevating compounds.

CJC-1295 with DAC: 1–2 mg once per week, injected SubQ. When combined with Ipamorelin (the standard protocol), inject both at the same time in the same or different SubQ sites. Mod GRF 1-29 (CJC-1295 without DAC): 100–200 mcg per injection, 1–3 times daily (typically matched to Ipamorelin doses). More injections, more precise pulsatility, preferred by practitioners who prioritize natural GH rhythm. With Ipamorelin: The standard combination is CJC-1295 DAC 1–2 mg weekly + Ipamorelin 200–300 mcg 1–3x daily. The Ipamorelin injections create the acute GH pulses; CJC-1295 sustains the elevated GH baseline. Cycle length: 12-week protocols are common, with periodic monitoring of IGF-1 levels to guide dosing.

CJC-1295 is a research chemical not approved for human use in the US or most jurisdictions. It is legally purchasable for research purposes. WADA prohibits it as a GH secretagogue. Prescribing physicians in the US do not typically prescribe CJC-1295 DAC; Sermorelin and compounded Ipamorelin are more commonly the prescription-route equivalents.

CJC-1295 + Ipamorelin: The canonical GH optimization stack. GHRH-pathway + ghrelin-pathway stimulation produces synergistic GH output. This combination is the standard protocol for most GH peptide users. CJC-1295 + Ipamorelin + BPC-157: For athletes focused on recovery, adding BPC-157 to the GH stack addresses both systemic GH/IGF-1 elevation and targeted tissue repair. CJC-1295 DAC vs. Mod GRF 1-29 decision: Users who prioritize convenience choose CJC-1295 DAC; users who prioritize pulsatile physiology choose Mod GRF 1-29 with more frequent dosing.

CJC-1295 — Common Questions